Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
308
Total raised
£4.1B
disclosed amounts
This month
£27.8M
raised so far
The financing round was backed by Bayland Capital and founding shareholder CN Innovations to accelerate product development and commercial expansion.
"We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimize their workflows."
The funding will support the Edinburgh biotechnology firm in bringing its FDA-approved medical device to international markets.
"Early diagnosis and treatment of tooth decay is essential, allowing patients to reverse the damage to their teeth before it is too late. This investment will enable us to launch our innovative product to global markets – first in the US and eventually in the UK – leading to faster diagnoses and early intervention treatments."
DSW Ventures and XTX Ventures backed the pre-seed round, which will fund prototype optimisation and technical validation.
"InvenireX has developed an exciting platform technology with promising data and early customer traction. This round will help get the technology into the hands of users who can further validate it and drive the company forward into full commercialisation. It’s been a pleasure to work with the InvenireX team who are incredibly talented, dynamic and open to collaboration."
Mercia Ventures and BGF led the Series A round to help the biotechnology firm commercialise its RNA sequencing technology.
"Genetic sequencing has come a long way since its inception in the 1970’s. The industry is now moving past short-read towards long-read sequencing, with long-read RNA sequencing being one of the most exciting new developments in biotechnology. We believe our solution could accelerate a new wave of biotechnology innovations. We are pleased to receive backing from some of the UK’s leading life science investors, which highlights its potential. The funding will help us to pursue our mission to reveal the unseen world of RNA and unlock exciting new applications."
Pfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
